Amgen Inc. [NASDAQ:AMGN]: Analyst Rating and Earnings
Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to Amgen Inc. [AMGN] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. On average, stock market experts give AMGN an Outperform rating. Its stock price has been found in the range of 163.31 to 210.19. This is compared to its latest closing price of $191.12.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Amgen Inc. [AMGN] is sitting at 2.33. This is compared to 1 month ago, when its average rating was 2.35.
For the quarter ending in Dec-18 Amgen Inc. [AMGN] generated $6.23 billion in sales. That’s 6.67% higher than the average estimate of $5.84 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Tue 23 Apr (In 32 Days).
Fundamental Analysis of Amgen Inc. [AMGN]
Now let’s turn to look at profitability: with a current Operating Margin for Amgen Inc. [AMGN] sitting at +43.44 and its Gross Margin at +82.75, this company’s Net Margin is now 35.30%. These measurements indicate that Amgen Inc. [AMGN] is generating considerably more profit, after expenses are accounted for, compared to its market peers.
This company’s Return on Total Capital is 19.30, and its Return on Invested Capital has reached 19.60%. Its Return on Equity is 44.48, and its Return on Assets is 11.47. These metrics all suggest that Amgen Inc. is doing well at using the money it earns to generate returns.
Turning to investigate this organization’s capital structure, Amgen Inc. [AMGN] has generated a Total Debt to Total Equity ratio of 271.43. Similarly, its Total Debt to Total Capital is 73.08, while its Total Debt to Total Assets stands at 51.09. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 236.08, and its Long-Term Debt to Total Capital is 63.56. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.
What about valuation? This company’s Enterprise Value to EBITDA is 10.07 and its Total Debt to EBITDA Value is 2.76. The Enterprise Value to Sales for this firm is now 5.20, and its Total Debt to Enterprise Value stands at 0.25. Amgen Inc. [AMGN] has a Price to Book Ratio of 9.81, a Price to Cash Flow Ratio of 11.46 and P/E Ratio of 15.22. These metrics all suggest that Amgen Inc. is more likely to generate a positive ROI.
Shifting the focus to workforce efficiency, Amgen Inc. [AMGN] earns $1,105,488 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 6.97 and its Total Asset Turnover is 0.32. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.57 and its Current Ratio is 2.79. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Amgen Inc. [AMGN] has 637.00M shares outstanding, amounting to a total market cap of $122.23B. Its stock price has been found in the range of 163.31 to 210.19. At its current price, it has moved by -8.71% from its 52-week high, and it has moved 17.50% from its 52-week low.
This stock’s Beta value is currently 1.20, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 54.58. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Amgen Inc. [AMGN] a Reliable Buy?
Shares of Amgen Inc. [AMGN], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.